Orchid performs clinical-grade whole-genome sequencing on Day-5 embryo biopsies (4–5 cells from ~120-cell blastocysts), claiming roughly 100× more data than standard PGT that surveys <1% of DNA. Their CLIA/CAP lab combines optimized chemistry, bioinformatics and variant curation to report monogenic and polygenic risks; next milestone is proving neonatal genome concordance with the embryo sequence.